StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
No sell-side coverage available for KALV yet.
Common for small-cap names, ETFs, recent IPOs, and ADRs without US-listed sell-side coverage. When analysts publish, ratings appear here within one business day.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-14 | $26.81 | $26.76 | -0.19% | 3.5M |
| 05-15 | $26.78 | $26.73 | -0.19% | 8.9M |
| 05-18 | $26.77 | $26.76 | -0.04% | 2.0M |
| 05-19 | $26.75 | $26.77 | +0.06% | 8.0M |
| 05-20 | $26.77 | $26.81 | +0.15% | 5.5M |
Aggregated from Polygon's per-article sentiment classifications. Educational — sentiment is descriptive, not predictive.
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
Indicator values from Polygon. Educational only — single- indicator triggers in isolation are not a complete trading signal.
KalVista Pharmaceuticals Inc is a pharmaceutical company developing and delivering oral therapies for individuals affected by rare diseases with unmet needs. The company applies its knowledge in the kallikrein-kinin system (KKS) and oral drug discovery to develop small-molecule protease inhibitor medicines to address the needs of patients with diseases driven by plasma kallikrein and Factor XIIa. Its FDA-approved product EKTERLY (sebetralstat) is a novel, orally delivered, small-molecule plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged twelve years and older.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Metric | Q1 2026 2026-03-31 | Annual 2025 2025-12-31 | Q3 2025 2025-09-30 | Q3 2025 2025-07-31 |
|---|---|---|---|---|
Revenue | $40.86M | $49.08M | $13.69M | $1.43M |
Operating Income | $-23.44M | $-112.04M | $-154.74M | $-59.01M |
Net Income | $-23.49M | $-109.50M | $-158.91M | $-60.10M |
EPS (Diluted) | $-0.43 | $-2.03 | $-2.97 | $-1.12 |
Total Assets | $328.92M | $335.38M | $339.93M | $215.50M |
Total Liabilities | $348.57M | $338.09M | $322.93M | Not available |
Cash & Equivalents | $213.77M | $229.34M | $243.50M | $124.30M |
Free Cash Flow OCF − CapEx | $-14.58M | $-83.33M | $-128.85M | $-54.79M |
Shares Outstanding | 51.24M | 50.90M | 50.54M | 50.34M |
Latest Form 13F-HR disclosures from the curated Super Investors list. Click through to see each manager's full long book.